Kyowa Kirin Co Ltd
TSE:4151

Watchlist Manager
Kyowa Kirin Co Ltd Logo
Kyowa Kirin Co Ltd
TSE:4151
Watchlist
Price: 2 204.5 JPY 0.02% Market Closed
Market Cap: 1.2T JPY

Kyowa Kirin Co Ltd
Investor Relations

Kyowa Kirin Co., Ltd. stands as a notable presence in the global pharmaceutical landscape, having evolved from its roots in Japan into a significant force in medical innovation. This company, originally established from the merger of Kyowa Hakko Kogyo and Kirin Pharma, focuses on the development and commercialization of biopharmaceuticals that tackle complex medical conditions, primarily within the fields of oncology, nephrology, immunology, and neurology. With a strategy deeply rooted in research and development, Kyowa Kirin harnesses its proprietary antibody technologies and innovative approaches to deliver therapeutic solutions, fostering partnerships that expand its impact and reach. Their commitment to scientific progress is supplemented by a robust pipeline of investigational drugs, demonstrating their dedication to addressing unmet medical needs.

Kyowa Kirin operates primarily on a business model that derives revenues from the successful commercialization of its pharmaceutical products. The company navigates the delicate balance between high-stakes investment in R&D and the potential high rewards that come from developing effective new treatments. By consistently bringing innovative therapies to market, they generate revenue through direct sales, collaborations, and licensing agreements within both domestic and international spheres. Additionally, their strategic alliances with biotech firms and research institutions globally enable them to enhance their R&D capabilities, ensuring a steady flow of new drugs that sustain their growth and solidify their competitive edge in the highly regulated and competitive pharmaceutical sector.

Show more
Loading

Earnings Calls

2019 Q3
Feb 1, 2019
Show Transcript
Previous
Next
Seven Bank sees steady growth and improved profitability in Q3.
2019 Q3
Feb 1, 2019

In the third quarter, Seven Bank reported ordinary income of JPY 111.4 billion, a year-on-year increase of JPY 16.7 billion, while ordinary profit rose by JPY 2.1 billion to JPY 32.1 billion. Despite a net profit of JPY 7.5 billion due to prior impairments, the company remains on track to meet its full-year forecast. Moving forward, the year-end dividend has been increased from JPY 5 to JPY 6 per share, totaling JPY 11 annually. Enhanced electronic money services and the expansion of ATM operations are expected to support steady growth in transactions, even amidst competitive pressures.

Management

Mr. Masashi Miyamoto Ph.D.
President, CEO & Representative Director
No Bio Available
Mr. Motohiko Kawaguchi
CFO & Managing Executive Officer
No Bio Available
Mr. Yutaka Osawa M.B.A.
CCO, Executive VP & Representative Director
No Bio Available
Kazuki Nemoto
Head of Global Legal
No Bio Available
Hiroki Nakamura
Global Corporate Communications Head
No Bio Available
Hiroshi Sonekawa
Managing Executive Officer, VP and Head of Sales & Marketing Division
No Bio Available
Shoko Itagaki
Executive Officer & Chief People Officer
No Bio Available
Mr. Takeyoshi Yamashita Ph.D.
Chief Medical Officer, Senior Managing Executive Officer & Director
No Bio Available
Yasuo Fujii M.B.A.
Chief Strategy Officer, VP & Managing Executive Officer
No Bio Available
Jean-David Rafizadeh-Kabe J.D., M.D.
Head of Global Operational Transformation
No Bio Available

Contacts

Address
TOKYO-TO
Chiyoda-ku
Otemachi Financial City Grand Cube, 1-9-2, Ote-machi
Contacts
+81352057200.0
www.kyowakirin.co.jp